<DOC>
	<DOC>NCT01422824</DOC>
	<brief_summary>This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment. Data will be collected from patients receiving once monthly Mircera according to standard of care and local labelling during 12 months of treatment.</brief_summary>
	<brief_title>An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Stage IV chronic kidney disease, on haemodialysis Chronic renal anemia, on maintenance ESA treatment Hemoglobin concentration between 10.0 an 12 g/dL Continuous maintenance epoetin therapy with the same dosing interval during the previous month Contraindications to ESA treatment (e.g. hypersensitivity, noncontrolled hypertension) Hemoglobinopathies (e.g. homozygous sicklecell disease, thalassemia of all types) Anemia due to hemolysis, pure red cell aplasia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>